SELLAS Life Sciences Announces Appointment of Barbara A. Wood as Executive Vice President, General Counsel and Corporate Secr...
March 21 2018 - 8:45AM
SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a
clinical-stage biopharmaceutical company focused on novel cancer
immunotherapies for a broad range of cancer indications, today
announced the appointment of Barbara A. Wood as Executive Vice
President, General Counsel and Corporate Secretary.
“We are pleased to welcome Barbara to our executive team.
Barbara has extensive experience both as a biotech executive and a
corporate lawyer, along with valuable expertise in licensing,
acquisitions, divestitures, collaborations, intellectual
property, and strategic corporate development as well as commercial
matters, which will undoubtedly support the continued growth and
success of SELLAS,” said President and CEO, Angelos Stergiou, M.D.,
ScD h.c. “As we continue our maturation into a late-stage
development company and advance galinpepimut-S (GPS), our lead
product candidate, to Phase 3 clinical trials, Barbara’s leadership
and executive and legal experience will be of immense value.”
“I am excited to join SELLAS’ dynamic leadership team and look
forward to contributing to the Company’s growth at this critical
time,” said Ms. Wood. “I am eager to work with the SELLAS team to
realize the potential of SELLAS’ promising pipeline.”
Ms. Wood joins SELLAS having most recently served as Senior Vice
President, General Counsel and Secretary for Ophthotech
Corporation, where she supported corporate growth by advising on
commercial and collaborative agreements and transactions,
securities laws compliance and key strategic and legal issues.
Before joining Ophthotech in 2013, she served as Senior Vice
President and General Counsel at OSI Pharmaceuticals, where she
built the company’s legal department and served as a key member of
the senior management team through the company’s acquisition by
Astellas Pharma in 2010. Earlier in her career, she was a Partner
at Squadron Ellenoff, where she focused on mergers and
acquisitions, biotechnology, licensing, securities and venture
capital matters.
Ms. Wood holds a B.A. in Classics and Economics from Connecticut
College and a J.D. from Columbia University School of Law.
About SELLAS Life Sciences Group
SELLAS is a clinical-stage biopharmaceutical company focused on
novel cancer immunotherapeutics for a broad range of cancer
indications. SELLAS’ lead product candidate, galinpepimut-S (GPS),
is licensed from Memorial Sloan Kettering Cancer Center and targets
the Wilms Tumor 1 (WT1) protein, which is present in an array of
tumor types. GPS has potential as a monotherapy or in
combination to address a broad spectrum of hematologic malignancies
and solid tumor indications. SELLAS has Phase 3 clinical
trials planned (pending funding availability) for GPS in two
indications, acute myeloid leukemia (AML) and malignant pleural
mesothelioma (MPM) and is also developing GPS as a potential
treatment for multiple myeloma and ovarian cancer. SELLAS
plans to study GPS in up to four additional indications.
SELLAS has received Orphan Drug designations from the U.S. Food
& Drug Administration (FDA), as well as the European Medicines
Agency, for GPS in AML and MPM; GPS also received Fast Track
designation for AML and MPM from the FDA.
For more information on SELLAS, please visit
www.sellaslifesciences.com.
Investor Contact:Will O’ConnorStern Investor
Relations, Inc.212-362-1200ir@sellaslife.com
David Moser, JDSELLAS Life Sciences Group,
Inc.813-864-2571info@sellaslife.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024